Key result
The Gyro C1E3 centrifugal pump caused similar in vitro platelet activation to the Capiox pump, but significantly higher activation than the HPM-15 pump (p=0.006 for beta-TG and p=0.029 for PF4).
Why the study?
Does the Gyro C1E3 centrifugal pump cause different levels of platelet activation compared to the Terumo Capiox and Nikkiso HPM-15 pumps in an in vitro model?
Population
Fresh human blood in an in vitro model
Comparison
Gyro C1E3 centrifugal pump vs Terumo Capiox and Nikkiso HPM-15 centrifugal pumps
Design
Preclinical
Authors
Loading...
Does not support changing pump selection; leaves open whether in vitro activation differences affect clinical hemocompatibility.
Does the Gyro C1E3 centrifugal pump cause different levels of platelet activation compared to the Terumo Capiox and Nikkiso HPM-15 pumps in an in vitro model?
p-value: p=0.006 and 0.029
In vitro evaluation demonstrates that the Gyro C1E3 centrifugal pump induces similar platelet activation to the Capiox pump, but significantly more than the HPM-15 pump.
Kawahito et al. (2000) studied this question. Gyro C1E3 centrifugal pump vs. Terumo Capiox and Nikkiso HPM-15 pumps was evaluated on Rate of increase (RI) for beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) (p=0.006 and 0.029). The Gyro C1E3 centrifugal pump caused similar in vitro platelet activation to the Capiox pump, but significantly higher activation than the HPM-15 pump (p=0.006 for beta-TG and p=0.029 for PF4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: